Autolus Therapeutics (NASDAQ:AUTL) Shares Gap Down – What’s Next?

Autolus Therapeutics plc (NASDAQ:AUTL) gapped down before the market opened on Tuesday . The stock had previously closed at $2.18, but opened at $2.12. Autolus Therapeutics shares last traded at $2.14, with a volume of 615,672 shares traded.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $10.00 price target on shares of Autolus Therapeutics in a report on Thursday, December 5th. The Goldman Sachs Group raised Autolus Therapeutics from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $7.00 to $7.60 in a research report on Monday, November 18th. Finally, Redburn Atlantic upgraded Autolus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 price target on the stock in a research note on Friday, November 15th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Autolus Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $10.40.

Autolus Therapeutics Price Performance

The firm has a market capitalization of $580.08 million, a price-to-earnings ratio of -1.80 and a beta of 1.99. The stock has a 50 day moving average of $3.37 and a 200 day moving average of $3.76.

Autolus Therapeutics (NASDAQ:AUTL) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.10). During the same quarter last year, the company earned ($0.26) EPS. Analysts predict that Autolus Therapeutics plc will post -0.94 earnings per share for the current year.

Institutional Trading of Autolus Therapeutics

Several hedge funds have recently made changes to their positions in the stock. Wellington Management Group LLP grew its stake in Autolus Therapeutics by 35.4% during the 3rd quarter. Wellington Management Group LLP now owns 24,220,226 shares of the company’s stock worth $87,919,000 after buying an additional 6,330,392 shares during the last quarter. FMR LLC increased its holdings in shares of Autolus Therapeutics by 44.6% in the 3rd quarter. FMR LLC now owns 17,773,873 shares of the company’s stock worth $64,519,000 after acquiring an additional 5,478,706 shares during the period. Great Point Partners LLC lifted its position in Autolus Therapeutics by 195.0% in the 2nd quarter. Great Point Partners LLC now owns 3,441,667 shares of the company’s stock valued at $11,977,000 after purchasing an additional 2,275,000 shares during the last quarter. Armistice Capital LLC boosted its stake in Autolus Therapeutics by 33.8% during the 2nd quarter. Armistice Capital LLC now owns 6,250,000 shares of the company’s stock valued at $21,750,000 after purchasing an additional 1,578,000 shares during the period. Finally, Bank of New York Mellon Corp grew its position in Autolus Therapeutics by 74.5% in the 2nd quarter. Bank of New York Mellon Corp now owns 2,531,688 shares of the company’s stock worth $8,810,000 after purchasing an additional 1,080,897 shares during the last quarter. Institutional investors own 72.83% of the company’s stock.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.